Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05960097 · ClinicalTrials.gov registry record · Phase 2
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 692
- Enrollment target
NCT05960097: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT05960097 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 692 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (420% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05960097, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 692 participants
- Enrollment target
Study Summary
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine. The purpose of Part B of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccine under three different storage conditions.
Interventions
- BIOLOGICAL CV0701 mRNA COVID-19 Vaccine (Low dose)
- BIOLOGICAL CV0701 mRNA COVID-19 Vaccine (Medium dose)
- BIOLOGICAL CV0701 mRNA COVID-19 Vaccine (High dose)
- BIOLOGICAL CV0601 mRNA COVID-19 Vaccine
- BIOLOGICAL Control vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 2 |
What the finished NCT05960097 record still lists
NCT05960097 is an interventional study that assigns participants to a tested intervention. The registered 692 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (420% higher).
The record links to 0 conditions, and to 5 interventions - of which CV0701 mRNA COVID-19 Vaccine (Low dose) is the first listed.
NCT05960097 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05960097 about?
NCT05960097 is a clinical study titled "A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults". The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine. The purpose of Part B of this study is to assess the immune response...
What is the current status of trial NCT05960097?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 692 participants. The study started on 2023-08-01. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT05960097?
The interventions under investigation include: CV0701 mRNA COVID-19 Vaccine (Low dose) (BIOLOGICAL), CV0701 mRNA COVID-19 Vaccine (Medium dose) (BIOLOGICAL), CV0701 mRNA COVID-19 Vaccine (High dose) (BIOLOGICAL), CV0601 mRNA COVID-19 Vaccine (BIOLOGICAL), Control vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05960097?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05960097's enrollment target sits among peer trials
692 46th of 2000 higher than 1,955 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI